These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 33123352)

  • 1. SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia.
    Fernandez-Fernandez B; Sarafidis P; Kanbay M; Navarro-González JF; Soler MJ; Górriz JL; Ortiz A
    Clin Kidney J; 2020 Oct; 13(5):728-733. PubMed ID: 33123352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease.
    Mima A
    Adv Ther; 2021 May; 38(5):2201-2212. PubMed ID: 33860925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure.
    McMurray JJV; Wheeler DC; Stefánsson BV; Jongs N; Postmus D; Correa-Rotter R; Chertow GM; Hou FF; Rossing P; Sjöström CD; Solomon SD; Toto RD; Langkilde AM; Heerspink HJL;
    JACC Heart Fail; 2021 Nov; 9(11):807-820. PubMed ID: 34446370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
    Aguilar-Gallardo JS; Correa A; Contreras JP
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease - Implications for Clinical Practice.
    Fitchett DH
    Eur Endocrinol; 2018 Sep; 14(2):40-49. PubMed ID: 30349593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
    Waijer SW; Vart P; Cherney DZI; Chertow GM; Jongs N; Langkilde AM; Mann JFE; Mosenzon O; McMurray JJV; Rossing P; Correa-Rotter R; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL
    Diabetologia; 2022 Jul; 65(7):1085-1097. PubMed ID: 35445820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
    Wheeler DC; Stefánsson BV; Jongs N; Chertow GM; Greene T; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Toto RD; Sjöström CD; Langkilde AM; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Jan; 9(1):22-31. PubMed ID: 33338413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Role of Dapagliflozin in Clinical Practice.
    Zargar AH; Trailokya AA; Ghag S; Pawar R; Aiwale A; Zalke A
    J Assoc Physicians India; 2021 Sep; 69(9):11-12. PubMed ID: 34585897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations.
    Usman MS; Siddiqi TJ; Anker SD; Bakris GL; Bhatt DL; Filippatos G; Fonarow GC; Greene SJ; Januzzi JL; Khan MS; Kosiborod MN; McGuire DK; Piña IL; Rosenstock J; Vaduganathan M; Verma S; Zieroth S; Butler J
    J Am Coll Cardiol; 2023 Jun; 81(25):2377-2387. PubMed ID: 37344038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis.
    Tian L; Ai S; Zheng H; Yang H; Zhou M; Tang J; Liu W; Zhao W; Wang Y
    Front Pharmacol; 2022; 13():986186. PubMed ID: 36506550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium/glucose cotransporter 2 inhibitors in chronic kidney disease and heart failure: ready for prime time in patients without diabetes.
    Vlasschaert C; Sidhu B; Silver SA
    Curr Opin Nephrol Hypertens; 2021 May; 30(3):361-368. PubMed ID: 33767064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced.
    Zannad F; Ferreira JP; Pocock SJ; Zeller C; Anker SD; Butler J; Filippatos G; Hauske SJ; Brueckmann M; Pfarr E; Schnee J; Wanner C; Packer M
    Circulation; 2021 Jan; 143(4):310-321. PubMed ID: 33095032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
    Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
    Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
    Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
    Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons from a pre-specified meta-analysis of sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure: Time for new clinical recommendations.
    Kotit S
    Glob Cardiol Sci Pract; 2023 May; 2023(2):e202314. PubMed ID: 37351098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Preserved trial.
    Sharma A; Ferreira JP; Zannad F; Pocock SJ; Filippatos G; Pfarr E; Petrini M; Kraus BJ; Wanner C; Packer M; Butler J; Anker SD
    Eur J Heart Fail; 2023 Aug; 25(8):1337-1348. PubMed ID: 37062851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors.
    Fernández-Fernandez B; Sarafidis P; Soler MJ; Ortiz A
    Clin Kidney J; 2023 Aug; 16(8):1187-1198. PubMed ID: 37529652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
    Chertow GM; Vart P; Jongs N; Toto RD; Gorriz JL; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefánsson BV; Langkilde AM; Wheeler DC; Heerspink HJL;
    J Am Soc Nephrol; 2021 Sep; 32(9):2352-2361. PubMed ID: 34272327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.